Related Experiment Video
Updated: Apr 18, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against
Laura A Johnson1, Luis Sanchez-Perez2, Carter M Suryadevara2
1Translational Research Program and Department of Pathology and Laboratory Medicine; Abramson Cancer Center; Perelman School of Medicine; University of Pennsylvania ; Philadelphia, PA USA.
Abstract:
CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.
Insights
Chimeric antigen receptor (CAR) therapy shows cancer treatment promise but causes unexpected toxicity. New models reveal CAR therapy induces immunogenic cell death, offering potential cures.
Area of Science:
- Immunology
- Oncology
- Biomedical Engineering
Background:
- Chimeric antigen receptor (CAR) therapy is a promising cancer treatment.
- Preclinical models often fail to predict CAR therapy's toxicity in normal tissues.
- There is a need for more physiologically relevant models for toxicity testing.
Purpose of the Study:
- To develop more accurate preclinical models for CAR therapy toxicity testing.
- To investigate the mechanisms underlying CAR therapy-induced toxicity.
- To explore the potential for CAR therapy to induce immunogenic cell death.
Main Methods:
- Generation of novel, physiologically relevant models for CAR toxicity assessment.
- In vivo and in vitro testing of CAR therapy efficacy and toxicity.
- Analysis of cellular death pathways induced by CAR therapy.
Main Results:
- CAR therapy was found to induce immunogenic cell death (ICD) in normal tissues.
- The developed models provided better prediction of CAR therapy toxicity compared to traditional methods.
- ICD induction suggests a potential mechanism for complete tumor eradication.
Conclusions:
- Physiologically relevant models are crucial for accurate preclinical CAR toxicity evaluation.
- CAR therapy can induce immunogenic cell death, a mechanism with therapeutic potential.
- Further research into ICD could lead to improved CAR therapy strategies and cures.
